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Abstract
Introduction: The aim of this work is to design a selection algorithm for total allowable error (TEa) source using a graphic tool that, by 
integrating internal (IQC) and external (EQC) quality control performances, enables the laboratory to evaluate which TEa source better 
fits the test analytical performance. 
Materials and methods: Two analytical performance indicators (bias and Sigma metrics) were estimated for 23 biochemistry tests during 2016. 
Bias was estimated on the EQC, and Sigma metrics was calculated through the results obtained in the IQC. The Sigma metrics was charted as a func-
tion of the bias (TEa%). Following the proposed algorithm (considering the hierarchy in the Milan 2014 consensus), the TEa was evaluated depending 
on two areas. One area in the chart was defined as the objective area in which the used TEa is the appropriate one for the analytical performance of 
the test under evaluation. For any test located outside this area, a performance re-evaluation was required using another source of TEa. 
Results: In 19 out of 23 evaluated tests, the resulting analytical performance allowed for the selection of biologic variability as TEa source. In the 
four remaining cases, TEa sources of lesser hierarchy were selected.
Conclusion: The graphic tool designed together with the proposed algorithm enabled the laboratory to standardize the selection procedure of the 
most appropriate TEa for the test analytical performance.
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Introduction
Patient safety, and errors made in the healthcare 
system have been a very important issue in past 
years. Laboratory medicine services are an essen-
tial part of the delivery of healthcare; providing 
significant medical information vital to diagnosis, 
treatment and prevention of diseases. It is estimat-
ed that 60 - 70% of medical decisions are based on 
laboratory results (1-2). 
It has been published that from the total number 
of errors associated to healthcare system, labora-
tories may participate in up to 12% (3). The distri-
butional study of different errors in the medical 
laboratory can be done according to the different 
phases. Laboratory activities can be typically di-
vided in the preanalytical, analytical and postana-
lytical phase. It was shown that the largest per-
centage of errors is found within the preanalytical 
phase, followed by the postanalytical phase and 
lastly, the analytical phase (3). However, according 
to these phases, the evaluation of the impact of 
such errors shows that when a negative impact is 
created in the patient’s health care, 52% of the 
time the root cause is associated to an error in the 
analytical phase (4). Therefore, the incorporation 
of quality assurance strategies during the analyti-
cal phase is paramount to avoid errors with a high 
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probability of generating a negative impact in pa-
tients’ healthcare. 
The management of analytical processes in a clini-
cal laboratory involves: a) defining quality require-
ment based on medical usefulness; b) selecting 
measurement procedures and evaluating impreci-
sion and inaccuracy to be sure the observed ana-
lytical performance satisfies the requirements; and 
c) selecting or designing quality control (QC) pro-
cedures based on both the quality requirements 
and the performance are observed for the meas-
ured procedure (5-7). 
The Sigma metrics model provides an objective 
process to evaluate the performance of a method. 
This metric quantifies processes performance as a 
rate of defects per million opportunities. Sigma 
metrics combine bias, precision and total allowable 
error (TEa) and can be calculated using the formula 
Sigma = [(TEa – bias) / CV], where TEa is the analyti-
cal objectives (analytical specifications), and bias 
and CV (coefficient of variation) are the indicators of 
systematic and random errors, respectively (7-8).
Sigma metrics depend directly on the selected 
TEa. There are a great number of analytical specifi-
cations sources (TEa) found in the literature, that 
the laboratory faces the difficulty of having to 
choose the most appropriate quality specifications 
for use in quality planning. For this reason, when 
selecting TEa, it is essential to be based on rele-
vant international references on the subject, such 
as the hierarchy of these specifications during the 
Milan consensus in 2014 (revision to the Stockholm 
conference in 1999) (9).
Based on the concepts presented hereby, the pur-
pose of this work is to design a tool that makes the 
selection of analytical objectives easier, which not 
only refer to a known international hierarchy, but 
are also attainable with current technology. 
Materials and methods
Study design
This study was carried out at LAC - Laboratorio de 
Análisis Clínicos, Uruguay in December 2017. LAC is 
a Uruguayan Clinical Laboratory accredited ac-
cording to UNIT-ISO 15189:2012 standard since 
2011 (10). In Uruguay, a laboratory that meets this 
standard can be accredited by the Uruguayan Ac-
creditation Organism (OUA). A retrospective, de-
scriptive study was performed in LAC based on 
the external and internal quality control perfor-
mances.
The laboratory designed a selection algorithm for 
TEa source using a graphic tool that, by integrat-
ing internal (IQC) and external quality (EQC) con-
trol performances, enables the laboratory to eval-
uate which TEa source best fits the test analytical 
performance and to design a selection algorithm 
for TEa source.
Methods
Two analytical performance indicators (bias and 
Sigma metrics) were estimated for 23 biochemis-
try tests during the same period of time, from Jan-
uary to December 2016. The evaluated assays were 
processed in a homogeneous system, analytical 
platform Architect ci8200 (Abbott Diagnostics, 
Montevideo, Uruguay), according to the 
manufacturer ś specifications and using proprie-
tary reagents and reference materials as calibra-
tors (Table 1). The following tests were included in 
this study: albumin (Alb), alanine aminotransferase 
(ALT), aspartate aminotransferase (AST), amylase 
(AMY), alkaline phosphatase (ALP), total bilirubin 
(BT), direct bilirubin (BD), calcium (Ca), cholesterol 
(CHOL), creatinine (CREA), gamma glutamyl-trans-
ferase (GGT), glucose (Glc), high density lipopro-
tein-cholesterol (HDL), iron (Fe), lactate dehydro-
genase (LD), magnesium (Mg), phosphate (Phos), 
potassium (K), total protein (TP), sodium (Na), tri-
glycerides (Tg), uric acid (UA) and urea.
Bias was first of the selected performance indica-
tors and based on the 2016 Clinical Chemistry ex-
ternal quality assurance services (EQAS) BIO-RAD 
program results. The measured error was estimat-
ed based on the difference between the laborato-
ry result and the best estimate of the true value 
(peer group mean) from each of the 12 surveys. 
The bias was estimated as the root mean squared 
of the measured error from the 12 surveys and ex-
pressed as a percentage of the total allowable er-
ror [Bias (TEa %)].
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Analyte Method Calibrator list number - name Calibrator´s reference material and method
Alb bromocresol green, colorimetric 1E65 - Multiconstituent calibrator ERM-DA470/IFCC, gravimetric
ALT IFCC, UV without P5P, 37 °C None NADH molar extinction factor/ molar extinction factor
AMY CNPG3 substrate None IFCC reference procedure (2006)
ALP p-nitrophenyl phosphate None IFCC reference procedure (2011)
AST IFCC, UV without P5P, 37 °C None NADH molar extinction factor/molar extinction factor
TB diazonium salt 1E66 - Bilirubin calibrator NIST SRM 916, Doumas
DB diazo reaction 1E66 - Bilirubin calibrator Human samples, Doumas
Ca arsenazo III, colorimetric 1E65 - Multiconstituent calibrator NIST SRM 956, IDMS
CHOL enzymatic, cholesterol oxidase/cholesterol esterase 1E65 - Multiconstituent calibrator Abell-Kendall, volumetric
CREA kinetic, alkaline picrate 1E65 - Multiconstituent calibrator NIST SRM 914, IDMS
GGT L-Gamma-glutamyl-3-car-boxy-4-nitroanilide substrate None
3-carboxy-4-nitroalanine molar extinction 
factor/ Molar extinction factor
Glc hexokinase 1E65 - Multiconstituent calibrator NIST SRM 965, IDMS
HDL cholesterol oxidase/cholesterol esterase, colorimetric 1E68 - HDL calibrator human samples, CDC Abell-Kendall
Fe ferene 1E65 - Multiconstituent calibrator NIST SRM 3126, gravimetric
LD IFCC, UV Lactate-pyruvate None IFCC reference procedure (2002)
Mg arsenazo 1E65 - Multiconstituent calibrator NIST SRM 956, IDMS
Phos UV, phosphomolybdate 1E65 - Multiconstituent calibrator NIST 186-I/2186-I, gravimetric
K ion-selective electrode 1E46 - ICT Serum calibrator NIST SRM flame photometry
TP biuret 1E65 - Multiconstituent calibrator NIST SRM 927, gravimetric
Na ion-selective electrode 1E46 - ICT Serum calibrator NIST SRM, flame photometry
Tg enzymatic, glycerol phosphate oxidase 1E65 - Multiconstituent calibrator ACS grade glycerol, gravimetric
UA uricase, colorimetric 1E65 - Multiconstituent calibrator NIST SRM 913, gravimetric
Urea UV, urease 1E65 - Multiconstituent calibrator NIST SRM 912, gravimetric
ERM – European reference material. IFCC - International federation of Clinical Chemistry and Laboratory Medicine. UV- ultraviolet. 
P5P - pyridoxal 5`- phosphate. CNPG3 - 2-chloro-4-nitrophenyl-α-D-maltotrioside. NIST - National Institute of Standards and 
Technology. SRM - standard reference materials. IDMS - isotope dilution mass spectrometry. CDC - Centers for disease control and 
prevention. ACS - American chemical society. Alb - albumin. ALT - alanine aminotransferase. AST - aspartate aminotransferase. AMY 
- amylase. ALP - alkaline phosphatase. BT – bilirubin, total. BD – bilirubin, direct. Ca - calcium. CHOL - cholesterol. CREA - creatinine. 
GGT - glutamyl-transferase. Glc - glucose. HDL - high-density lipoprotein cholesterol. Fe - iron. LD - lactate dehydrogenase. Mg - 
magnesium. Phos – inorganic phosphate. K – potassium.TP - total protein. Na - sodium. Tg - triglycerides. UA - uric acid. 
Table 1. Methodological characteristics of analytes
Sigma metrics was the second performance indi-
cator selected and calculated through the results 
obtained in the internal quality control with an in-
terlaboratory participation scheme (Lyphochek 
Assayed Chemistry Control, Level 1 and 2) corre-
sponding to 2016 using the following formula: Sig-
ma metrics = [TEa (%) – bias (%)] / CV (%).
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Five different TEa sources were chosen to estimate 
the performance indicators selected by the labo-
ratory: bias (TEa%) and Sigma metrics. Biological 
variation (BV), RiliBÄK (guidelines of the German 
medical association for the quality assurance of 
laboratory medical examinations), RCPA (Royal 
College of Pathologists of Australasia), CLIA (Clini-
cal Laboratory Improvement Amendments) and 
the state of the current technology (hereinafter, 
BioRad EQAS Performance) estimated by the labo-
ratory were the selected TEa sources (11-14). 
The BioRad EQAS performance estimation was 
done through the weighted CV (%) calculation of 
the peer group of 12 surveys from the 2016 Clinical 
Chemistry EQAS BIO-RAD program. It was consid-
ered that the state of the current technology 
would be three times the weighted CV (15-16).
A graphic tool was used to integrate the perfor-
mance of the external and internal quality evalua-
tion programs in which the Sigma metrics was 
charted as a function of the bias (TEa%)2016 and 
four areas have been identified in the chart (Figure 
1).
The work algorithm designed by the laboratory to 
select the TEa source is summarized in Figure 2.
Alternatively, in order to prioritize the selection of 
the TEa source of lesser hierarchy, for the 23 evalu-
ated tests the Sigma metrics and bias performance 
indicators bias (TEa%) were calculated using differ-
ent TEa sources: RCPA, RiliBÄK, CLIA and BioRad 
EQAS performance.
The performance obtained by TEa source was re-
lated to the area in the chart in which it was locat-
ed and the percentage of assays in a certain area 
of the chart according TEa source was calculated, 
which was to enable the identification of the most 
appropriate TEa source according to their perfor-
mance in the laboratory tests. This is the TEa 
source that should be selected as the first option 
in cases where minimal biological variability could 
not be used.
Statistical analysis
Twelve monthly EQAS® reports were used to calcu-
late the bias:  
Measured
Error (%) 
Peer group target value – our result
Peer group target value 
x 100=
Bias (%) = 
n
1 ∑ (x1 + x2 +  ........ xn) ,  
2 2 2
where x is the measured error (%) for each individ-
ual survey and n is the number of surveys. The bias 
was expressed as a percentage of the total allowa-
ble error, bias (TEa%), using the following formula:




Annual Sigma metrics for each test was estimated 
as the average of the monthly Sigma metrics of 
the limiting quality control level (worst perfor-
mance control level). Sigma metrics was calculated 
through the results obtained in the internal quality 
BioRad control with an interlaboratory participa-
tion scheme corresponding to 2016 using the fol-
lowing formula: Sigma metrics = [TEa (%) – bias 
(%)] / CV(%), where CV (%) was the analytical coef-
ficient of the test method variation and the bias, 
the difference between the laboratory mean and 
the peer group. CV and bias were collected during 
Figure 1. Graphic tool used to integrate the performance of ex-
ternal and internal quality evaluation programs. Area A: 5.15 < 
sigma < 12 and bias (%TEa)2016 < 50 or sigma >12 and 25 < bias 
(%TEa)2016 < 50. Area B: bias (%TEa)2016 ≤ 25% and sigma ≥ 12. 
Area C: sigma ≤ 5.15 and bias (%TEa)2016 ≤ 50% or sigma ≥ 5.15 
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Figure 2. Selection algorithm for TEa source. The algorithm presented was designed on the basis of the areas defined in Figure 1.
the same time frame and the Sigma metrics was 
calculated monthly.
Results
The main results of this work using desirable bio-
logical variability as TEa source are presented in 
Figure 3, in which the tests were grouped by loca-
tion in the chart. From a total of 23 tests, 8 were 
located in area A of the chart: ALT, AMY, AST, CHOL, 
GGT, Phos, K, and urea. There were five tests locat-
ed in the area B of the chart, BT, BD, Fe, Tg, and UA. 
The performance was re-evaluated for these tests 
using optimal biological variability as TEa source. 
The result obtained in this re-evaluation was that 
every test was located in area A of the chart. The 
six tests in area C of the chart (Alb, ALP, CREA, TP, 
HDL, and LD) were re-evaluated using minimal bi-
ological variability as TEa source. The result was 
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TP which continued to be in area C of the chart. 
Performance of TP was re-evaluated using TEa 
from other sources (Table 2). The result indicated 
that the test was in area A of the chart for all the 
evaluated sources. The four tests in area D (Glc, Ca, 
Na and Mg) of the chart were re-evaluated using 
minimal biological variability as source. Only two 
test changed areas, Glc moved to area A and Mg, 
to area C. The tests that continued to be in area D 
were re-evaluated using TEa from other sources 
(RiliBÄK, RCPA, CLIA and BioRad EQAS perfor-
mance), the location of the tests performance with 
the different sources is represented in Table 2. Ac-
cording to the results obtained for TP and Mg the 
laboratory would be able to select among the fol-
lowing sources: RCPA, RiliBÄK, CLIA and BioRad 
EQAS performance, given that any of these sourc-
es fell in area A of the chart. For Na RiliBÄK was the 
only TEa source that made the test be located in 
area A, and for Ca the laboratory would be able to 
select among the following sources: RiliBÄK, CLIA 
and state of the art.
In 19 out of 23 evaluated tests the analytical per-
formance allowed for the selection of biologic var-
iability as TEa source.
According to the results presented in Table 3 and 
4, the TEa source that best adjusts itself to tests 
performance in the laboratory is RiliBÄK because 
the performance indicators of 19 of the evaluated 
tests with this source fall into area A or B of the 
chart. RiliBÄK as a source of TEa are not available 
for AMY, BD, HDL and Fe.
Bias (TEa, %) Sigma Metrics
Analyte RCPA RiliBÄK CLIA Biorad EQAS performance RCPA RiliBÄK CLIA
Biorad EQAS 
performance
TP 13.0 6.5 6.5 8.9 6.28 11.1 11.1 7.5
Ca 52.3 20.9 28.2 33.7 2.9 9.2 9.3 5.1
Mg 32.3 17.4 10.4 21.4 5.7 8.2 14.3 6.7
Na 37.6 15.0 28.2 19.3 2.6 6.4 3.6 4.8
RCPA - Royal College of Pathologists of Australasia. RiliBÄK - guidelines of the German medical association for the quality assurance 
of laboratory medical examinations.. CLIA - Clinical Laboratory Improvement Amendments. TP - total protein. Ca - calcium. Mg – 
magnesium. Na – sodium.
Table 2. Performance indicators according to selected TEa source
Figure 3. Comprehensive evaluation of the assays studied.
Area A: ALT, AMY, AST, CHOL, GGT, Phos, K, Urea; Area B: BT, BD, 
Fe, Tg, UA; Area C: Alb, ALP, CREA, TP, HDL, LD; Area D: Ca, Glc, 
Mg, Na.
X-axis indicates the value of Six Sigma. TEa – total allowable 
error. Alb - albumin. ALT - alanine aminotransferase. AST - as-
partate aminotransferase. AMY - amylase. ALP - alkaline phos-
phatase. BT – bilirubin, total. BD – bilirubin, direct. Ca - calcium. 
CHOL - cholesterol. CREA - creatinine. GGT – gamma glutamyl-
transferase. Glc - glucose. HDL - high density lipoprotein cho-
lesterol.  Fe - iron. LD - lactate dehydrogenase. Mg - magne-
sium. Phos – inorganic phosphate. K - potassium; TP - total pro-
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Analyte RCPA RiliBÄK CLIA Biorad EQAS Performance
Alb Area A Area B Area A Area A
ALT Area C Area A Area A Area C
AMY Area A NA* Area B Area A
ALP Area A Area A Area B Area C
AST Area A Area A Area A Area C
BT Area A Area A Area B Area A
BD Area A NA* NA* Area C
Ca Area D Area A Area A Area C
CHOL Area A Area B Area B Area C
CREA Area C Area A Area A Area C
GGT Area C Area A NA* Area A
Glc Area A Area A Area A Area A
HDL Area C NA* Area B Area A
Fe Area A NA* Area A Area C
LD Area C Area A Area A Area C
Mg Area A Area A Area B Area A
Phos Area C Area B NA* Area C
K Area A Area A Area A Area C
TP Area A Area A Area A Area A
Na Area C Area A Area C Area C
Tg Area B Area B Area B Area A
UA Area B Area B Area B Area A
Urea Area A Area B Area A Area C
*NA – source not available (30,32). RCPA - Royal College of 
Pathologists of Australasia. RiliBÄK - guidelines of the German 
medical association for the quality assurance of laboratory 
medical examinations. CLIA - Clinical Laboratory Improvement 
Amendments. Alb - albumin. ALT - alanine aminotransferase. 
AST - aspartate aminotransferase. AMY - amylase. ALP - alkaline 
phosphatase. BT – bilirubin, total. BD – bilirubin, direct. Ca - 
calcium. CHOL - cholesterol. CREA - creatinine. GGT – gamma 
glutamyl-transferase. Glc - glucose. HDL - high density 
lipoprotein cholesterol. Fe - iron. LD - lactate dehydrogenase. 
Mg - magnesium. Phos – inorganic phosphate. K - potassium; 
TP - total protein. Na - sodium. Tg - triglycerides. UA - uric acid.
Table 3. Analyte location in the chart according to the evalu-
ated performance with different TEa sources
TEa source Area A Area B Area C Area D
RCPA 56.5% 8.7% 30.4% 4.4%
RiliBÄK 68.4% 31.6% 0.0% 0.0%
CLIA 55.0% 40.0.% 5.0% 0.0%
Biorad EQAS 
performance 43.5% 0.0% 56.5% 0.0%
TEa – total allowable error. RCPA - Royal College of Pathologists 
of Australasia. RiliBÄK - guidelines of the German medical 
association for the quality assurance of laboratory medical 
examinations. CLIA - Clinical Laboratory Improvement 
Amendments.  EQAS - external quality assurance services. TP- 
total protein. Ca-calcium. Mg – magnesium. Na – sodium.
Table 4. Distribution of the assays’ location in the chart accord-
ing to TEa source expressed in percentage
evaluation of the analytical system stability 
throughout time; 2) it allows the evaluation of the 
analytical performances in relation to the selected 
performance specifications; 3) it works as a tool for 
the alignment of analytical performance specifica-
tions in accordance to the hierarchical criteria ex-
posed in the 2014 Milan consensus (9). 
Internal quality control as an analytical perfor-
mance indicator allows for the estimation of preci-
sion in the evaluated concentrations. This is added 
to the possibility of estimating the bias by using 
third opinion materials with robust even groups 
(15). These characteristics make it a good tool to 
evaluate each of the error components (systematic 
and random) separately and/or comprehensively 
through Sigma metrics.
External quality control as an analytical perfor-
mance indicator is complementary to internal con-
trol. It allows the evaluation of measurement pro-
cedures in concentrations that are not evaluated 
by the latter. Likewise, error quantification (meas-
urement error) is used as a way of evaluating the 
measuring precision of assays, because the result 
of each survey is effected by both error compo-
nents (systematic and random) being an expres-
sion of these integration. Moreover, the analysis of 
a group of surveys during a long period of time in 
which the analytical system has been stable allows 
for the estimation of another performance indica-
tor as the measuring bias.
Discussion
The model designed by our laboratory presents 
three main strengths: 1) it holds the ability of inte-
grating internal and external quality control per-
formances, which are two paramount tools for the 
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For the performance evaluation using said tools, it 
is highly important to define a margin of error. The 
level of performance required to facilitate clinical 
decision-making has been given a number of 
names. The currently most widely applied terms 
are quality specifications, quality goals, analytical 
performance goals and total allowable error (16). 
The TEa is the amount of error that can be tolerat-
ed without invalidating the medical usefulness of 
the analytical result. TEa is used to define accepta-
ble analytical performance for assessment of an 
individual instrument’s analytical performance, 
quality control validation and as a measure of 
agreement or comparability of results for analytes 
measured on different systems (17). 
In a 2013 review on improvements in quality and 
patient safety, Plebani emphasized the need for 
further improvements in analytical quality: “A bet-
ter analytical quality should be achieved by set-
ting and implementing evidence-based analytical 
quality specifications in everyday practice; if this 
will be done, rules for internal quality control and 
external quality assessment procedures would be 
more appropriate. Moreover, there is a compelling 
need for standardization programs aimed at im-
proving metrological traceability and correcting 
biases and systematic errors. Finally, more strin-
gent metrics, such as Six Sigma, should be largely 
introduced in clinical laboratories, to further im-
prove current analytical quality.” (18).
Due to the clinical impact that a wrongful selec-
tion of quality requirements may have and the 
great amount of analytical decisions that are made 
based upon it, it is paramount that laboratories es-
tablish clear procedures to align said selection. 
The proposed TEa selection algorithm is present-
ed as a possible solution to this problem. The flex-
ibility of the associated quality specifications 
based on biological variability allows having a 
wider range of allowable error to be selected for 
each assay without losing the TEa rank in hierar-
chy.  One of the difficulties covered by the model is 
how to proceed when the specifications based on 
biologic variability are unattainable. In these cas-
es, the algorithm proposes the selection of sourc-
es of lesser hierarchy (third level in the 2014 Milan 
consensus). When this happens due to the great 
number of available sources, the laboratory is 
faced with selecting specifications that depend on 
the offered features by the industry in which there 
is an unclear relationship between the specifica-
tion adaptation and the clinical utility. Implicitly, 
when a TEa of this level is selected, we are estab-
lishing a minimum performance specification. This 
is linked to the state of technology in a certain an-
alytical context. 
Along these lines, the proposed method covers 
the main requirements based on the schemes of 
external quality evaluation as well as regulations 
linked to obtaining performances used in the ana-
lytical platform. The aim of this is to standardize 
the selection of a third level of hierarchy require-
ment against the others, in agreement with its ad-
aptation to the technical features attained by an 
analytical system stable in time.  It is worth noting 
too that the evaluated measuring procedures are 
accredited by Standard UNIT ISO 15189:2012.
We cannot fail to mention that there are cases in 
which the analytical specifications based even in 
the optimal level of biologic variability highly ex-
ceed those estimated through the state of current 
technology. For example, for BD, the optimal spec-
ification is 22.3%, whiles the estimated specifica-
tion through BioRad EQAS performance in 2017, 
was 12.7%. In these cases, the laboratory can de-
cide to use a requirement of lesser hierarchy (level 
3) in which the allowable error is lower adapting to 
the analytical system used and decreasing the 
amount of variation added to true test result vari-
ability.
The obtained results show a correct suitability for 
the proposed algorithm, its implementation being 
possible in the evaluated analytical platform. In 
addition, Sigma metrics was the performance indi-
cator that ended up defining the TEa in all cases. 
No assays were found in which the analytical per-
formance estimated through the internal quality 
control (Sigma metrics) had a better performance 
than the estimated through the external quality 
control [Bias (TEa%)]. This can be explained by the 
different factors that can be considered extra-ana-
lytical inherent to the manipulation of the internal 
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quality control material (i.e. storage, aliquotation, 
freezing, analytes stability, multiple daily proce-
dures, etc.) while the impact of these factors in the 
external evaluation programs is significantly lower 
or non-existent (depending on the case). There-
fore, it can be said that the Sigma metrics would 
be underestimated in this model, as the variables 
used do not affect the decisions made about pa-
tients’ samples.
The Sigma metrics values are useful in setting the 
internal quality control acceptability criteria and 
control strategy based on the Westgard rules (19-
21). For analytes attaining sigma below 5.15, a mul-
ti-rules procedure has to be used and/or quality 
control should be run at a higher frequency to im-
prove the probability of error detection. This fact, 
added to the Sigma metrics underestimation, im-
plies a questionable rise in the complexity of the 
quality control system regarding daily operation 
of control material procedures and evaluation of 
the results. It is for this reason that it is decided to 
evaluate the performance indicators using TEa 
sources of lesser hierarchy that allow to locate the 
assay in Area A of the chart, which is associated to 
rules of simple control with high probability of er-
ror detection and low probability of false rejec-
tion.
The decision to choose requirements of lesser hi-
erarchy was also because the only assays that pre-
sented a critical sigma performance lower to three 
using minimal biologic variability as TEa source 
were Na and CA. This coincides with how demand-
ing this requirement is, which makes it unattaina-
ble due to the current state of technology. The 
quality specification for minimal biologic variabili-
ty is of 1.1% and 3.6% for Na and Ca, respectively. 
Assuming a hypothetical scenario where there is 
no bias, CV should be lower than 0.21% for Na and 
lower than 0.69% for Ca to reach a sigma perfor-
mance higher than 5.15 which makes it a difficult 
requirement to attain currently. For this reason, a 
quality requirement of lesser hierarchy had to be 
selected for these two cases.
For 15 out of the 23 studied assays, the selected 
quality requirement of biologic variability was 
higher than 10%. This quality requirement is more 
permissive the assay tolerates a greater impreci-
sion and bias without modifying its location in the 
chart.
In six assays (Alb, UA, CHOL, K, Mg and TP), the se-
lected quality requirement of biologic variability 
was within 5.4% and 10%. Only for Mg and TP bio-
logic variability could not be selected as quality re-
quirement. The minimal quality requirements of 
biologic variability are 5.4% and 7.2% for TP and 
Mg, respectively. Considering the zero-bias model, 
CV should be lower than 1.05% for TP and lower 
than 1.40% for Mg to reach a sigma performance 
higher than 5.15 which makes it a difficult require-
ment to attain. For this reason, a quality require-
ment of lesser hierarchy had to be selected for 
these two cases.
In regards to the selection of the TEa for its use as 
an specification of analytical performance, the re-
sults obtained by the laboratory, in this work, are 
consistent with those obtained in other published 
studies where it is concluded that biological varia-
bility represents, in many cases, a very difficult 
goal to achieve (i.e. Na, Ca, etc.) (22-25). For these 
assays the selection and use of TEa source of lesser 
hierarchy are essential, and this element should be 
considered as an input in any algorithm designed 
to decide which TEa goal is most appropriate for it. 
The algorithm developed by the laboratory seeks 
to combine the concepts of hierarchy and de-
mand. Stablishing biological variability as an initial 
goal for being the one with the highest hierarchy 
and also, usually, the most demanding. The idea 
implicit in this decision lies in generating a tool 
aligned to the continuous improvement of the 
processes, where the purpose is to identify in 
which assays the analytical goals could be attaina-
ble using more stringent quality goals such as bio-
logical variability instead of using less demanding 
goals that would allow too much tolerance of the 
processes, even when they are regulatory. At the 
same time, this algorithm allows to identify TEa 
goals that are too demanding for analytical perfor-
mance for some typical field assays.  At this point, 
it is worth mentioning that in those cases where 
there are regulatory requirements (mandatories, 
for instance CLIA) the laboratory should always 
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verify that the requirements selected, following 
the proposed algorithm, are more stringent than 
those established as mandatory by the corre-
sponding body.
The laboratory was faced with immense difficulty 
to apply this model due to the absence of IT tools 
that enabled the integration of performance indi-
cators associated to the internal and external qual-
ity control results. The existence of such an IT tool 
would significantly simplify the possibility of im-
plementing this model to laboratories, which 
would enable the standardization of the selection 
procedure for TEa.
The model designed by our laboratory presents 
some limitations which occasionally restrict its 
use. It must be considered that to estimate the 
bias the target value was considered as the best 
estimation of the true value defined by the value 
of the even group. It is also worth noting, there 
might be better estimations of the true value such 
as those values obtained through the analysis 
completed done over materials quantified by a 
reference method (reference materials). Further-
more, the model cannot be applied when a first 
opinion internal quality control is being used as 
peer group values are not known in these cases. 
This prevents the calculation of the bias and thus, 
the Sigma metrics. The usage of non-accredited 
external quality evaluation programs under Stand-
ard ISO 17043 does not ensure statistical robust-
ness for assigning the best estimation of the true 
value. Lastly, the model designed for the selection 
of the TEa has the limitation that the biologic vari-
ability is not available for all analytes.
In conclusion, the graphic tool designed together 
with the proposed algorithm enabled the labora-
tory to standardize the selection procedure of the 
most appropriate TEa for the test analytical perfor-
mance. 
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